CenterWell

I'll research this company.

CenterWell — company profile

Overview. CenterWell is the healthcare-services brand and operating segment of Humana Inc. (NYSE: HUM), headquartered in Louisville, Kentucky. The CenterWell name was introduced in March 2021 to unify Humana's payer-agnostic care businesses; the home-health and pharmacy re-branding was completed in 2022. It is not a separately listed company — it is a subsidiary/segment of Humana, which is publicly traded and remains primarily a Medicare Advantage insurer. CenterWell reports more than 34,000 employees. Humana guidance has put the CenterWell segment at roughly $25 billion or more in 2026 revenue, with about $6.1 billion reported in Q1 2026; these figures are from secondary/company reporting rather than a standalone CenterWell filing.

Products / services. Three main lines: (1) Senior primary care — CenterWell Senior Primary Care and Conviva Senior Primary Care, value-based senior clinics (300+ centers across roughly 15 states); (2) Home health — CenterWell Home Health, skilled nursing, therapy and post-acute coordination through ~350 branches in 38 states, substantially built from Humana's ~$8.1 billion acquisition of Kindred at Home (2021); and (3) Pharmacy — CenterWell Pharmacy and CenterWell Specialty Pharmacy, providing mail-order delivery, retail locations, OTC fulfillment and specialty-drug services. CenterWell is an operating healthcare provider, not a patent-holding entity.

Litigation posture. The tracked data show one case, with CenterWell as plaintiff and none as defendant. That single case is antitrust, not patent infringement: CenterWell Pharmacy, Inc. v. Celgene Corp. and Bristol Myers Squibb, No. 1:24-cv-06924 (S.D.N.Y., filed Sept. 13, 2024). It was consolidated into Louisiana Health Service & Indemnity Co. et al. v. Celgene, No. 1:23-cv-07871 (S.D.N.Y., Judge Edgardo Ramos) — the Southern District of New York, not a plaintiff-friendly Texas venue. CenterWell appears as an end-payor/direct purchaser rather than a patent enforcer.

Case context. The consolidated suit alleges Celgene/BMS unlawfully extended monopoly pricing on Pomalyst (pomalidomide) via Walker Process fraud on the Patent Office, sham patent litigation and reverse-payment settlements; the court dismissed the claims in March 2025 and denied leave to amend on March 30, 2026.